Evaluating Drug Induced Proarrhythmic Risk Using the CardioECR System
1,496 views
|
March 2, 2016
Cardiovascular toxicity is a leading cause of drug attrition. There is an urgent need for more predictive and higher throughput assays capable of providing mechanistic toxicity information earlier in the drug discovery and development process. In this webinar Dr. Haoyu Zeng of Merck Research Laboratories (West Point, PA) discusses his work using the new xCELLigence® RTCA CardioECR system in conjunction with iPSC cardiomyocytes to assess the cardiotoxic liability of compounds. He describes his experience using the CardioECR system to screen drugs as part of the FDA CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative. Specific topics covered include:
• An overview of in vitro cardiotoxicity screening
• The unique features of the CardioECR system – simultaneous monitoring of cardiomyocyte
contractility and field potential
• Results from the CiPA validation study at Merck using the CardioECR system
Dr. Haoyu Zeng received his B.S. in biology from the University of Science and Technology of China, and his Ph.D. in molecular pharmacology from Brown University, studying the nicotinic acetylcholine receptor with Dr. Edward Hawrot. Following his graduate work, he did postdoctoral training with Dr. Irwin Levitan at the University of Pennsylvania where he focused on calcium-activated potassium channels. Dr. Zeng was a senior scientist at SK Bioscience before joining Merck Safety Assessment as a senior pharmacologist in 2007. He is currently a principal scientist in Merck’s Department of Safety and Exploratory Pharmacology. He is the author/co-author of more than 12 manuscripts/book chapters and has presented at more than 10 scientific conferences.
For more information, please visit: http://www.aceabio.com/product/rtca-cardioecr/
